Eli Lilly and Company Q1 2026 Financial Results and Guidance Update

Eli Lilly and Company reported a significant increase in first-quarter 2026 revenue, up 56% to $19.8 billion, primarily driven by volume growth in Mounjaro and Zepbound, despite lower realized prices. Earnings per share (EPS) saw a substantial rise of 170% on a reported basis to $8.26 and 156% on a non-GAAP basis to $8.55. The company raised its full-year 2026 guidance, projecting revenues between $82.0 billion and $85.0 billion and non-GAAP EPS between $35.50 and $37.00. Key developments include the FDA approval of Foundayo (orforglipron) for obesity and positive Phase 3 results for several pipeline drugs. Lilly also announced agreements to acquire Orna Therapeutics, Centessa Pharmaceuticals plc., Kelonia Therapeutics, and Ajax Therapeutics, further bolstering its development pipeline.